• 1.

    Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1S276. doi: 10.1016/j.kint.2021.05.021

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Lafayette R, et al.; NefIgArd Trial Investigators. Efficacy and Safety of a Targeted-Release Formulation of Budesonide in Patients with Primary IgA Nephropathy (NefIgArd): 2-Year results from a randomised phase 3 trial. Lancet 2023; 402:859870. doi: 10.1016/S0140-6736(23)01554-4. Erratum: Lancet 2023; 402: 850. doi: 10.1016/S0140-6736(23)01851-2

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Medjeral-Thomas NR, et al. Complement activation in IgA nephropathy. Semin Immunopathol 2021; 43:679690. doi: 10.1007/s00281-021-00882-9

  • 4.

    Caravaca-Fontán F, et al. Targeting complement in IgA nephropathy. Clin Kidney J 2023; 16(Suppl 2):ii28ii39. doi: 10.1093/ckj/sfad198

  • 5.

    Barratt J, et al.; Cemdisiran Phase 2 Study Investigators and Collaborators. Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: A randomized controlled trial. Clin J Am Soc Nephrol (published online January 15, 2024). doi: 10.2215/CJN.0000000000000384

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Wheeler DC, et al.; DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215224. doi: 10.1016/j.kint.2021.03.033

    • PubMed
    • Search Google Scholar
    • Export Citation

The Role of Complement Blockade in the Management of IgA Nephropathy

Vinay Srinivasan Vinay Srinivasan, MD, MBA, is an assistant professor of medicine and the director of onconephrology at Cooper Medical School of Rowan University and Cooper University Hospital, Camden, NJ. Nasim Wiegley, MD, FASN, is an associate professor of medicine and the director of the Glomerular Diseases Clinic at the University of California Davis Medical Center, Sacramento.

Search for other papers by Vinay Srinivasan in
Current site
Google Scholar
PubMed
Close
and
Nasim Wiegley Vinay Srinivasan, MD, MBA, is an assistant professor of medicine and the director of onconephrology at Cooper Medical School of Rowan University and Cooper University Hospital, Camden, NJ. Nasim Wiegley, MD, FASN, is an associate professor of medicine and the director of the Glomerular Diseases Clinic at the University of California Davis Medical Center, Sacramento.

Search for other papers by Nasim Wiegley in
Current site
Google Scholar
PubMed
Close
Restricted access
Save